4.7 Article

Pre-Morbid Body Mass Index and Mortality After Incident Heart Failure The ARIC Study

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 64, Issue 25, Pages 2743-2749

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2014.09.067

Keywords

obesity paradox; outcomes; overweight; pre-morbid

Funding

  1. National Heart, Lung, and Blood Institute [HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, HHSN268201100012C]
  2. Abbott Diagnostic
  3. Amarin
  4. Amgen
  5. Eli Lilly
  6. Esperion
  7. GlaxoSmithKline
  8. Genentech
  9. Merck Co.
  10. Novartis
  11. Pfizer, Inc.
  12. Regeneron
  13. Roche
  14. Roche Diagnostic
  15. Sanofi-Synthelabo

Ask authors/readers for more resources

BACKGROUND Although obesity is an independent risk factor for heart failure (HF), once HF is established, obesity is associated with lower mortality. It is unclear if the weight loss due to advanced HF leads to this paradoxical finding. OBJECTIVES This study sought to evaluate the prognostic impact of pre-morbid obesity in patients with HF. METHODS In the ARIC (Atherosclerosis Risk In Communities) study, we used body mass index (BMI) measured >= 6 months before incident HF (pre-morbid BMI) to evaluate the association of overweight (BMI 25 to <30 kg/m(2)) and obesity (BMI >= 30 kg/m(2)) compared with normal BMI (18.5 to <25 kg/m(2)) with mortality after incident HF. RESULTS Among 1,487 patients with incident HF, 35% were overweight and 47% were obese by pre-morbid BMI measured 4.3 + 3.1 years before HF diagnosis. Over 10-year follow-up after incident HF, 43% of patients died. After adjustment for demographics and comorbidities, being pre-morbidly overweight (hazard ratio [HR]: 0.72; 95% confidence interval [CI]: 0.58 to 0.90; p = 0.004) or obese (HR: 0.70; 95% CI: 0.56 to 0.87; p = 0.001) had a protective association with survival compared with normal BMI. The protective effect of overweight and obesity was consistent across subgroups on the basis of a history of cancer, smoking, and diabetes. CONCLUSIONS Our results, for the first time, demonstrate that patients who were overweight or obese before HF development have lower mortality after HF diagnosis compared with normal BMI patients. Thus, weight loss due to advanced HF may not completely explain the protective effect of higher BMI in HF patients. (C) 2014 by the American College of Cardiology Foundation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available